secwatch.observer — SEC 8-K summary
======================================

Issuer:     NextCure, Inc. (NXTC)
CIK:        0001661059
Form:       8-K
Filed at:   2025-06-23T23:59:59+00:00
Accession:  0001558370-25-008789
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

NextCure stockholders elect directors, ratify auditor, approve reverse stock split at 2025 annual meeting
--------------------------------------------------------------------------------

- Elected Class III directors David Kabakoff, Michael Richman, and Stephen W. Webster for three-year terms expiring 2028.
- Ratified Ernst & Young LLP as independent auditor for fiscal year 2025 with 18.8M for, 1.4M against.
- Approved say-on-pay (11.3M for, 0.4M against) and frequency vote of every year (11.7M for).
- Approved amendment to certificate of incorporation to authorize reverse stock split when determined by the Board (18.2M for, 2.0M against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025008789/0001558370-25-008789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661059/000155837025008789/nxtc-20250620x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-008789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer